The NCRI Brain Group’s “Building a platform for early phase interventions in glioblastoma patients” Working Group sets out to achieve Priority 2 of the NCRI Brain Group Strategic Priorities: To develop a window of opportunity study, early phase trial or basket study for glioblastoma patients utilising targeted agents, immunotherapy and/or drug-RT combinations. 

By addressing this priority, we aim to work towards converting discovery science into patient benefit. This will include prioritising early evaluation of translational discoveries in patients and developing agile studies that can rapidly move into larger Phase III effectiveness trials.

You can see the full list of strategic priorities for the NCRI Brain Group here. 

Working Group members